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with baseline population characteristics may potentially con-
found these ﬁndings.
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OBJECTIVES: To examine treatment failure rates, disease-
related medical complications and health care costs among CAP
outpatients treated with levoﬂoxacin (LEVO) or amoxicillin/
clavulanate (AC). METHODS: Using adjudicated, commercial
health insurance claims data (PharMetrics, Inc.), patients with
an outpatient CAP diagnosis between July 2003 and December
2004, aged 18–64, with 6-months enrollment pre– and
post–diagnosis, receiving LEVO or AC monotherapy within 3
days of diagnosis, were identiﬁed. Patients with recent hospital-
ization (10 days), prior antibiotic therapy (30 days), or immuno-
compromised state were excluded. Treatment failure was deﬁned
as receipt of a renewal or alternative antibiotic claim, or hospi-
talization 28 days post–prescription claim. Complications and
infection related costs were tracked for 6-months post–
diagnosis. Demographic, clinical, pre–index utilization, and
study endpoints were evaluated via descriptive, univariate
(Wilcoxon and Chi-Square tests for continuous and dichotomous
variables, respectively) and multivariate techniques (logistic
regression for treatment failure and complications, General
Linear Model for costs). RESULTS: Of 4030 LEVO and 951 AC
patients analyzed, the cohorts had similar demographic and clin-
ical proﬁles (pre–diagnosis utilization and cost, comorbidity
burden, Charlson score), except age (LEVO vs AC: 45.8 vs. 42.7
y, p < 0.001), gender distribution (females 49.5% vs. 53.4%, p
< 0.001), and asthma prevalence (4.9% vs 6.8%, p = 0.017). The
AC group had a higher percentage (22.0% vs. 18.5%, p = 0.015)
and likelihood (OR = 1.27, 95% CI 1.07–1.52, p = 0.007) of
treatment failure than the LEVO group. The rates of infec-
tion–related complications were 8.6% for LEVO and 8.2% for
AC; (OR 1.12, 95% CI 0.80–1.56, p = 0.52). No difference was
observed in infection–related costs (mean ± SD: LEVO $1067 ±
3562 vs. AC $1159 ± 5874). CONCLUSION: LEVO and AC
groups were comparable. The LEVO group experienced signiﬁ-
cantly lower treatment failure, but no signiﬁcant differences in
complications or costs, compared to the AC group, in outpatient
CAP.
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OBJECTIVES: To examine treatment failure rates among com-
munity acquired pneumonia (CAP) patients treated with lev-
oﬂoxacin vs. macrolides (azithromycin, clarithromycin or
erythromycin) in an outpatient setting. METHODS: A post-hoc,
retrospective database analysis using eligibility (6-months pre
and post), medical and pharmacy claims from a large US com-
mercial health plan. Adults (≥18) with an outpatient primary
diagnosis of CAP between January 1, 2004 and March 31, 2005,
and treated within 3 days of diagnosis with oral levoﬂoxacin or
macrolides were included. Patients with a recent hospitalization
(10 days), prior antibiotic therapy (30 days), or immunocom-
promised state were excluded. Treatment failure was deﬁned as
receipt of receipt of renewal or alternative antibiotic claim, or
hospitalization for CAP within 30 days of initial therapy. Mul-
tivariate logistic regression compared treatment failure rates
between the two groups. Multivariate regression included all rel-
evant variables describing patient characteristics including age,
gender, region, Charlson comorbidity score, pre-existing respi-
ratory, cardiovascular disease and diabetes. An identical sub-
group analysis of patients ≥50 years old was conducted.
RESULTS: Of 7526 CAP patients included, 2968 (39.4%) were
treated with levoﬂoxacin and 4558 (60.6%) with a macrolide.
Levaquin patients were older (mean 48.7 vs. 43.7) and had a
more severe Charlson comorbidity status (mean 0.40 vs. 0.25).
Unadjusted treatment failure rates were 21.1% and 22.7% in
levoﬂoxacin and macrolide cohorts, respectively. After adjust-
ment, compared to macrolides, levoﬂoxacin patients were less
likely to fail treatment (OR = 0.84, 95% CI: 0.73, 0.94, P =
0.002). Of 2967 subjects ≥50 years old, 21.8% of levoﬂoxacin
and 25.4% of macrolide patients failed treatment, respectively;
likelihood of treatment failure was signiﬁcantly lower for lev-
oﬂoxacin patients (OR = 0.79, 95% CI: 0.66, 0.94, P = 0.007).
CONCLUSION: Compared with macrolides, Levoﬂoxacin was
associated with lower treatment failure rates in CAP patients
treated in an outpatient setting. This difference was greater in
patients ≥50 years old.
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OBJECTIVES: Vancomycin is often considered ﬁrst-line for com-
plicated gram+ infections; however, a rise in resistant infections
in both hospital and community settings may impact efﬁcacy and
total cost of treatment. Our objective was to systematically eval-
uate the clinical efﬁcacy and resource use/economic characteris-
tics of vancomycin in recent randomized clinical trials (RCT) or
economic studies for treatment of complicated gram+ infections,
such as skin and soft tissue infections (SSTI), including methi-
cillin-resistant staphylococcus aureus (MRSA). METHODS: A
literature search was conducted in PubMed, EMBASE, IPA, and
infectious disease abstract databases to identify clinical or eco-
nomic studies of vancomycin published from 2000–2006. Clin-
ical outcomes data were synthesized by study design, infection
type, MRSA status, intent to treat (ITT) efﬁcacy, microbiologic
cure, MRSA efﬁcacy, and adverse events (AEs). Efﬁcacy data
were pooled when possible. Economic data abstracted included
hospital length of stay (LOS), length of treatment (LOT), and
cost of treatment (COT) adjusted to 2006 US$. RESULTS:
Twelve studies (including 5 RCTs with 4 in SSTI) were identiﬁed
reporting speciﬁc clinical efﬁcacy outcomes and/or economic
data. The ITT average efﬁcacy (range) for vancomycin 1 gm IV
q12hr for SSTIs was 85% (76.9–88.5%) and microbiologic cure
was 89% (77–97.6%). For MRSA SSTIs, efﬁcacy was lower at
68% (50–81%). Incidence of drug-related AEs was 3.6–20.6%,
and drug-related discontinuations 4.5–5.8%. Hospital LOS
ranged from 8–15 days, and LOT 9–11 days. Resistance
